Amgen Inc. (BVMF:AMGN34)

Market Cap	954.12B
Revenue (ttm)	191.70B
Net Income (ttm)	37.33B
Shares Out	n/a
EPS (ttm)	68.93
PE Ratio	25.56
Forward PE	15.63
Dividend	1.27 (2.02%)
Ex-Dividend Date	Nov 19, 2025

Volume	15
Average Volume	522
Open	63.18
Previous Close	63.07
Day's Range	63.08 - 63.18
52-Week Range	48.40 - 75.12
Beta	0.45
RSI	50.76
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: AMGN34

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD